Literature DB >> 29493071

Long-wave plasma radiofrequency ablation for treatment of xanthelasma palpebrarum.

Adone Baroni1.   

Abstract

Xanthelasma palpebrarum is the most common type of xanthoma affecting the eyelids. It is characterized by asymptomatic soft yellowish macules, papules, or plaques over the upper and lower eyelids. Many treatments are available for management of xanthelasma palpebrarum, the most commonly used include surgical excision, ablative CO2 or erbium lasers, nonablative Q-switched Nd:YAG laser, trichloroacetic acid peeling, and radiofrequency ablation. This study aims to evaluate the effectiveness of RF ablation in the treatment of xanthelasma palpebrarum, with D.A.S. Medical portable device (Technolux, Italia), a radiofrequency tool working with long-wave plasma energy and without anesthesia. Twenty patients, 15 female and 5 male, affected by xanthelasma palpebrarum, were enrolled for long-wave plasma radiofrequency ablation treatment. The treatment consisted of 3/4 sessions that were carried out at intervals of 30 days. Treatments were well tolerated by all patients with no adverse effects and optimal aesthetic results. The procedure is very fast and can be performed without anesthesia because of the low and tolerable pain stimulation. Long-wave plasma radiofrequency ablation is an effective option for treatment of xanthelasma palpebrarum and adds an additional tool to the increasing list of medical devices for aesthetic treatments.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  long-wave plasma radiofrequency ablation; nonsurgical radiofrequency treatment; plasma energy treatment; xanthelasma palpebrarum treatment

Mesh:

Year:  2018        PMID: 29493071     DOI: 10.1111/jocd.12509

Source DB:  PubMed          Journal:  J Cosmet Dermatol        ISSN: 1473-2130            Impact factor:   2.696


  1 in total

1.  Plasma Radiofrequency Ablation for Scar Treatment.

Authors:  Adone Baroni; Pasquale Verolino
Journal:  J Clin Med       Date:  2021-12-27       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.